Profluent Stock for Accredited Investors

Biotech / Life Sciences
By UpMarket Research  |  Last updated: September 2026
CEO Ali Madani Founded 2022 HQ Berkeley, US

Profluent is an AI biotechnology company that builds foundation models to design novel proteins. It uses machine learning and wet-lab validation to support applications in therapeutics, enzymes, and other life sciences use cases. In November 2025, Profluent raised $106 million in its Series B at a $0.50278 billion post-money valuation, led by Altimeter Capital and Bezos Expeditions (Business Wire and Forbes).

Access to pre-IPO shares is available to accredited investors through UpMarket.

Last Reported Valuation
$503M
Series B, 11/19/25, Business Wire and Forbes
UpMarket Estimate
$538M
Based on UpMarket valuation model
Previous Round Valuation
$155M
Series A, Mar 2024

How to Invest in Profluent Through UpMarket

Profluent shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.

Step 01

Verify accredited investor status

Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.

Step 02

Create an UpMarket account

Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.

Step 03

Review available Profluent offerings

Full offering memoranda and risk disclosures provided before any commitment is required.

Step 04

Complete subscription documents

Review and sign subscription agreement. All documents handled digitally through the platform.

Step 05

Fund your investment

Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundAmount raisedValuation
Nov 2025 Series B $106M $503M
Mar 2024 Series A $155M

Profluent's most recent reported round is its Series B, announced November 19, 2025. It raised $106 million at a reported post-money valuation of $502.8 million, led by Altimeter Capital and Bezos Expeditions. Source: Business Wire and Forbes. Data as of September 27, 2026.

Why Investors Are Watching Profluent

Growth Signal

Profluent raises $106M to scale frontier AI protein models

Profluent announced a $106 million round co-led by Altimeter Capital and Bezos Expeditions, lifting total funding to $150 million. The company said the capital will scale its frontier AI models for programmable biology across therapeutics, diagnostics, agriculture, and biomanufacturing.

Competitive Moat

AI models design proteins from natural-language prompts

Profluent says its models let scientists describe desired protein properties in human language and return DNA recipes for custom proteins. The company pairs large language models with wet-lab validation to design novel functional proteins beyond natural sequence space.

Market Opportunity

Programmable biology targets therapeutics, diagnostics, agriculture

Profluent said its platform is aimed at transforming how therapeutics, diagnostics, agriculture, and biomanufacturing solutions are developed. Air Street noted the new financing supports expansion across three major verticals and a path toward an AI-designed therapeutic in a human patient.

Interested in Profluent stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.

Request access →

Profluent Leadership Team

Ali Madani
CEO

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

Profluent Stock FAQ

No. As of March 2026, Profluent is a private company and does not trade on any public stock exchange. Accredited investors can access Profluent shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.

Profluent does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.

Yes. Accredited investors can indicate interest in Profluent shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.

Pre-IPO investments carry significant risks. Profluent shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.

The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.

UpMarket's valuation estimate is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.

Profluent was valued at $503M in its November 2025 Series B. Accredited investors can request Profluent access through UpMarket.

Invest in Profluent Request access